← BCI Directory Company

Neurable

Boston consumer neurotechnology company that builds EEG sensing into headphones and licenses its brain-signal software to other hardware makers. It put its own Neurable One headphones on sale in the US on 1 October 2026, the day after California's governor signed AB 1883, which bars employers from using AI tools to collect workers' neural data from 2027.

Overview

Neurable is a Boston company, led by chief executive Ramses Alcaide, that reads brain activity through EEG sensors built into headphones and scores focus and cognitive load. It closed a $35 million Series A in December 2025, taking total funding to $65 million. With Master & Dynamic it makes the MW75 Neuro headphones, which also anchor Neurable for Teams, an employer programme pitched at raising productivity and reducing burnout.

Licensing and own products

On 28 April 2026 Neurable opened its technology to licensing by other hardware makers. Named partners include HP’s HyperX gaming brand, the research platform iMotions, MeSpace and the US Air Force Research Laboratory. On 1 October 2026 it put Neurable One on sale in the US at $499. The over-ear headphones carry 12 EEG sensors in the ear pads and store brain activity whenever worn with the app open, a feature Neurable calls Brain Data Banking. Neurable names helmets and hearing protection among target form factors for its licensed sensing.

Regulatory exposure

California’s AB 1883, signed on 30 September 2026, bars employers from 1 January 2027 from using AI-enabled workplace surveillance tools to collect employees’ neural data, with an exception for tools used to ensure safety. Personal purchases fall outside the law, but an employer issuing EEG headphones to California staff for productivity could be exposed. In the EU, consumer neural wearables that infer attention or emotional state, including Neurable’s MW75 Neuro, fall within the AI Act transparency obligations that took effect on 2 August 2026.

Why it matters

Neurable is testing whether consumer brain sensing scales through licensing to established brands. Its employer offering sits squarely where neural-data rules are tightening, so demand from California employers and compliance in Europe will shape the business case.

Coverage on InsideBCI